Lack of Plasminogen Activator Inhibitor-1 Enhances the Preventive Effect of DX-9065a, a Selective Factor Xa Inhibitor, on Venous Thrombus and Acute Pulmonary Embolism in Mice [PDF]
, 2003 En Shu +4 more
openalex +1 more source
Bispecific nanobody® as a new pharmacological drug for the selective inhibition of Trypsin‐3
British Journal of Pharmacology, Volume 182, Issue 19, Page 4578-4591, October 2025.Abstract Background and Purpose Proteolytic balance is dysregulated in many diseases, with proteases playing critical roles in pathological pathways. A high level of Trypsin‐3 expression has been implicated as a significant mediator of tumour progression and metastasis, and this protease is associated with poor prognosis for patients in various cancers.
Melissa David +9 more
wiley +1 more source
Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity [PDF]
, 2003 G.M.T. Vogel +5 more
openalex +1 more source
RBM39 Promotes Base Excision Repair to Facilitate the Progression of HCC by Stabilising OGG1 mRNA
Cell Proliferation, Volume 58, Issue 10, October 2025.Targeting RBM39 attenuates BER via destabilising OGG1 mRNA and potentiates KBrO3‐induced oxidative stress in HCC. Our study represents a valuable treatment strategy combining indisulam and an oxidative stress inducer in HCC. ABSTRACT Targeting base excision repair (BER) has been an attractive strategy in cancer therapeutics.
Hongda An +7 more
wiley +1 more source
International Journal of Laboratory Hematology, Volume 47, Issue 5, Page 923-930, October 2025.ABSTRACT Introduction Argatroban is routinely monitored using activated partial thromboplastin time (APTT), with a recommended target range of 1.5–3.0 times. Although this range was established based on clinical trial data, including several APTT reagents, the differences in reactivity among APTT reagents remain unclear.
Osamu Kumano +6 more
wiley +1 more source
Urine-based point-of-care testing for factor-Xa-inhibitors in acute ischemic stroke patients: a feasibility study. [PDF]
Front Neurol, 2023 Doeppner TR +7 more
europepmc +1 more source
In vivo Evaluation of DX-9065a, a Synthetic Factor Xa Inhibitor, in Experimental Vein Graft
, 1996 Dong-Ik Kim +4 more
openalex +2 more sources
A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement [PDF]
, 2006 Bengt I. Eriksson +9 more
openalex +1 more source
Antithrombotic drug and its clinical indication. Factor Xa Inhibitor. Oral Xa inhibitor (DX-9065a).
, 1996 Masahide Yamazaki
openalex +2 more sources